Hydrocortisone

Suppliers

Names

[ CAS No. ]:
50-23-7

[ Name ]:
Hydrocortisone

[Synonym ]:
Medicort
11b,17,21-Trihydroxyprogesterone
17a-Hydroxycorticosterone
H-Cort
(11β)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
11β,17,21-Trihydroxyprogesterone
Cleiton
Hydrocortisone
MFCD00011654
(11β)-11,17,21-Trihydroxy-pregn-4-ene-3,20-dione
Hydroxycorticosterone
Hydrocort
Kendall's compound F
(11b)-11,17,21-trihydroxypregn-4-ene-3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
17-hydroxycorticosterone
Hydrocorticosterone
11,17,21-trihydroxy-pregn-4-ene-3,20-dione
Hytone
Alacort
Signef
(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one
Efcortelin
Hydroxycortisone
Hycort
pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11b)-
hidrocortisona
Zenoxone
hydrocortisonum
CCN 90306A
Pregn-4-ene-3,20-dione, 11β,17,21-trihydroxy-
HVB
Hydrocortal
wycort
Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11β)-
Optef
Hydroskin
Eye-Cort
EINECS 200-020-1
17α-Hydroxycorticosterone
11β,17α,21-Trihydroxypregn-4-ene-3,20-dione

Chemical & Physical Properties

[ Density]:
1.3±0.1 g/cm3

[ Boiling Point ]:
566.5±50.0 °C at 760 mmHg

[ Melting Point ]:
211-214 °C(lit.)

[ Molecular Formula ]:
C₂₁H₃₀O₅

[ Molecular Weight ]:
362.460

[ Flash Point ]:
310.4±26.6 °C

[ Exact Mass ]:
362.209320

[ PSA ]:
94.83000

[ LogP ]:
1.43

[ Vapour Pressure ]:
0.0±3.5 mmHg at 25°C

[ Index of Refraction ]:
1.595

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: GM8925000

CHEMICAL NAME :: Cortisol

CAS REGISTRY NUMBER :: 50-23-7

LAST UPDATED :: 199801

DATA ITEMS CITED :: 45

MOLECULAR FORMULA :: C21-H30-O5

MOLECULAR WEIGHT :: 362.51

WISWESSER LINE NOTATION :: L E5 B666 OV MUTJ A1 CQ E1 FV1Q FQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 150 mg/kg

TOXIC EFFECTS :: Biochemical - Metabolism (Intermediary) - effect on inflammation or mediation of inflammation

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 449 mg/kg

TOXIC EFFECTS :: Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >500 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 175 mg/kg/85D-I

TOXIC EFFECTS :: Endocrine - changes in adrenal weight Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 140 mg/kg/7D-I

TOXIC EFFECTS :: Endocrine - changes in thymus weight Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 62 mg/kg/11D-I

TOXIC EFFECTS :: Endocrine - other changes

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 210 mg/kg

SEX/DURATION :: female 14 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - uterus, cervix, vagina

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 80 mg/kg

SEX/DURATION :: female 14-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - biochemical and metabolic

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 50 mg/kg

SEX/DURATION :: female 18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - biochemical and metabolic

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 330 mg/kg

SEX/DURATION :: female 1-22 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - endocrine system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 220 mg/kg

SEX/DURATION :: female 9-19 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - endocrine system Reproductive - Effects on Newborn - biochemical and metabolic

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 200 mg/kg

SEX/DURATION :: female 14-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 500 mg/kg

SEX/DURATION :: female 13 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 50 mg/kg

SEX/DURATION :: female 16-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - other effects to embryo

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 35 mg/kg

SEX/DURATION :: female 7 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - uterus, cervix, vagina

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 10 mg/kg

SEX/DURATION :: female 11-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 400 mg/kg

SEX/DURATION :: female 11-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 400 mg/kg

SEX/DURATION :: female 11-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 156 mg/kg

SEX/DURATION :: female 11-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 200 mg/kg

SEX/DURATION :: female 12 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 400 mg/kg

SEX/DURATION :: female 11-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 200 mg/kg

SEX/DURATION :: female 12 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraplacental

DOSE :: 4 mg/kg

SEX/DURATION :: female 11 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 6 mg/kg

SEX/DURATION :: female 24-26 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - other neonatal measures or effects Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Ocular

DOSE :: 2945 ug/kg

SEX/DURATION :: female 6-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 12 mg/kg

SEX/DURATION :: female 16-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - homeostasis

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 150 mg/kg

SEX/DURATION :: female 12 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 333 mg/kg

SEX/DURATION :: female 10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 400 mg/kg

SEX/DURATION :: female 11 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: Unscheduled DNA synthesis

TYPE OF TEST :: DNA inhibition

TYPE OF TEST :: Cytogenetic analysis

TYPE OF TEST :: DNA inhibition

MUTATION DATA

TYPE OF TEST :: DNA inhibition

TEST SYSTEM :: Bird - chicken Embryo

DOSE/DURATION :: 450 pmol/L

REFERENCE :: NATUAS Nature. (Nature Subscription Dept., POB 1018, Manasguan, NJ 08736) V.1- 1869- Volume(issue)/page/year: 257,804,1975 *** REVIEWS *** TOXICOLOGY REVIEW CLPTAT Clinical Pharmacology and Therapeutics (St. Louis). (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1960- Volume(issue)/page/year: 5,480,1964 TOXICOLOGY REVIEW ADVPA3 Advances in Pharmacology. (New York, NY) V.1-6, 1962-68. For publisher information, see AVPCAQ. Volume(issue)/page/year: 4,263,1966 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 80429 No. of Facilities: 1374 (estimated) No. of Industries: 12 No. of Occupations: 15 No. of Employees: 28935 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 80429 No. of Facilities: 1396 (estimated) No. of Industries: 7 No. of Occupations: 20 No. of Employees: 36900 (estimated) No. of Female Employees: 21576 (estimated)

Safety Information

[ Symbol ]:

GHS08

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H361

[ Precautionary Statements ]:
P281

[ Personal Protective Equipment ]:
Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges

[ Hazard Codes ]:
Xn:Harmful

[ Risk Phrases ]:
R62;R63

[ Safety Phrases ]:
S36/37-S45

[ RIDADR ]:
2811.0

[ WGK Germany ]:
3

[ RTECS ]:
GM8925000

[ Hazard Class ]:
6.1

[ HS Code ]:
2937210000

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

Hydrocortisone acetate
Cortisone
17,21-Dihydroxy-pregn-5-ene-3,11,20-trione 3,20-Diethylene Ketal
11,17,21-Trihydroxy-pregn-5-ene-3,20-dione 3,20-Diethylene Ketal
21-acetoxy-17-hydroxy-pregn-4-ene-3,11,20-trione-3,20-disemicarbazone
Cortisone acetate
22-acetoxy-11β-hydroxy-3-oxo-23,24-dinor-5β-chol-17(20)ξ-ene-21-nitrile
21-acetoxy-11β,17α-dihydroxy-5β-pregnane-3,20-dione
11-Epicortisol
11α,17α,21-Trihydroxy-pregn-5-ene-3,20-dione 3,20-Diethylene Ketal

DownStream

Adrenosterone
11-Beta-hydroxyandrostenedione
Androst-4-en-3-one,11,17-dihydroxy-, (11b,17b)-
20-hydroxycortisol
20-α-DIHYDROCORTISOL
cortienic acid
Cortisone
Corticosterone
Androsta-4,9(11)-dien-3-one,17-hydroxy-, (17b)-

Customs

[ HS Code ]: 2937210000

Articles

Functional consequence of the MET-T1010I polymorphism in breast cancer.

Oncotarget 6(5) , 2604-14, (2015)

Major breast cancer predisposition genes, only account for approximately 30% of high-risk breast cancer families and only explain 15% of breast cancer familial relative risk. The HGF growth factor rec...

Cell-cell adhesions and cell contractility are upregulated upon desmosome disruption.

PLoS ONE 9(7) , e101824, (2014)

Desmosomes are perturbed in a number of disease states - including genetic disorders, autoimmune and bacterial diseases. Here, we report unexpected changes in other cell-cell adhesion structures upon ...

MYC is a critical target of FBXW7.

Oncotarget 6(5) , 3292-305, (2015)

MYC deregulation is a driver of many human cancers. Altering the balance of MYC protein levels at the level of transcription, protein stability, or turnover is sufficient to transform cells to a tumor...

Hydrocortisone
Hydrocortisone
Hydrocortisone-d2
Hydrocortisone-d4
Hydrocortisone-d3
D1-Hydrocortisone
1-(4-Aminopyridin-3-yl)-4-methylcyclohex-2-en-1-ol
4,4-Dimethyl-1-(pyridin-3-yl)cyclohex-2-en-1-ol
4,4-Dimethyl-1-(pyrazin-2-yl)cyclohex-2-en-1-ol
1-(Cyclohex-1-en-1-yl)-4,4-dimethylcyclohex-2-en-1-ol
1-(Butan-2-yl)-4,4-dimethylcyclohex-2-en-1-ol
1-(Cyclopropylmethyl)-4,4-dimethylcyclohex-2-en-1-ol
1-Cyclobutyl-4,4-dimethylcyclohex-2-en-1-ol
1-(2-Ethyl-5-hydroxycyclohexyl)-4-methyl-1,2-dihydropyrimidin-2-one
1-(2-Ethyl-5-hydroxycyclohexyl)-3,3-dimethylpyrrolidin-2-one
1-(2-Ethyl-5-hydroxycyclohexyl)-3-methyl-1,4-dihydropyridin-4-one

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.